Mineralys Therapeutics, Inc. (MLYS)
NASDAQ$14.25
Market Cap
$894.68M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
712 of 924
Rank in Industry
406 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
MLYS Insider Trading Activity
MLYS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $11,382,136 | 18 | 100 |
Related Transactions
| Rodman David Malcom | Chief Medical Officer | 0 | $0 | 4 | $467,839 | $-467,839 |
| Levy Adam Scott | CFO and Secretary | 0 | $0 | 4 | $1.64M | $-1.64M |
| Congleton Jon | Chief Executive Officer | 0 | $0 | 9 | $2.1M | $-2.1M |
| Slingsby Brian Taylor | 0 | $0 | 1 | $7.18M | $-7.18M |
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Insider Activity of Mineralys Therapeutics, Inc.
Over the last 12 months, insiders at Mineralys Therapeutics, Inc. have bought $0 and sold $11.38M worth of Mineralys Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Mineralys Therapeutics, Inc. have bought $16.3M and sold $6.67M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 555,555 shares for transaction amount of $7.5M was made by Samsara BioCapital GP, LLC (10 percent owner) on 2024‑02‑12.
List of Insider Buy and Sell Transactions, Mineralys Therapeutics, Inc.
| 2025-01-13 | Sale | Congleton Jon | Chief Executive Officer | 18,333 0.0359% | $9.06 | $166,082 | +6.68% | |
| 2025-01-13 | Sale | Levy Adam Scott | CFO and Secretary | 10,757 0.0211% | $9.10 | $97,864 | +6.68% | |
| 2024-11-11 | Sale | Rodman David Malcom | Chief Medical Officer | 5,026 0.0119% | $15.00 | $75,398 | -23.06% | |
| 2024-11-06 | Sale | Rodman David Malcom | Chief Medical Officer | 25,482 0.0603% | $15.03 | $383,066 | -21.50% | |
| 2024-10-11 | Sale | Congleton Jon | Chief Executive Officer | 15,271 0.0325% | $13.52 | $206,433 | -9.44% | |
| 2024-10-11 | Sale | Levy Adam Scott | CFO and Secretary | 10,757 0.023% | $13.57 | $146,004 | -9.44% | |
| 2024-07-24 | Sale | Slingsby Brian Taylor | 550,000 1.1293% | $13.05 | $7.18M | -12.51% | ||
| 2024-07-16 | Sale | Rodman David Malcom | Chief Medical Officer | 525 0.0012% | $15.00 | $7,876 | -17.15% | |
| 2024-07-11 | Sale | Congleton Jon | Chief Executive Officer | 15,746 0.0331% | $13.34 | $210,075 | -10.76% | |
| 2024-07-11 | Sale | Levy Adam Scott | CFO and Secretary | 10,757 0.0222% | $13.14 | $141,394 | -10.76% | |
| 2024-06-20 | Sale | Congleton Jon | Chief Executive Officer | 14,940 0.0276% | $11.73 | $175,237 | +3.76% | |
| 2024-06-18 | Sale | Congleton Jon | Chief Executive Officer | 16,607 0.0313% | $11.99 | $199,073 | +2.93% | |
| 2024-06-17 | Sale | Congleton Jon | Chief Executive Officer | 17,766 0.0343% | $12.25 | $217,712 | -0.66% | |
| 2024-06-14 | Sale | Congleton Jon | Chief Executive Officer | 16,229 0.032% | $12.52 | $203,163 | -3.54% | |
| 2024-06-13 | Sale | Congleton Jon | Chief Executive Officer | 39,961 0.0801% | $12.74 | $509,027 | -4.26% | |
| 2024-06-12 | Sale | Congleton Jon | Chief Executive Officer | 16,607 0.0334% | $12.77 | $212,013 | -3.53% | |
| 2024-06-11 | Sale | Levy Adam Scott | CFO and Secretary | 96,815 0.1971% | $12.94 | $1.25M | -6.39% | |
| 2024-05-09 | Sale | Rodman David Malcom | Chief Medical Officer | 100 0.0002% | $15.00 | $1,500 | -14.16% | |
| 2024-02-12 | Samsara BioCapital GP, LLC | 10 percent owner | 555,555 1.1801% | $13.50 | $7.5M | -14.40% | ||
| 2023-11-22 | Congleton Jon | Chief Executive Officer | 4,250 0.004% | $5.97 | $25,356 | +109.06% |
Total: 27
*Gray background shows transactions not older than one year
Insider Historical Profitability
17.1%
| Congleton Jon | Chief Executive Officer | 877608 1.3978% | $12.51M | 4 | 9 | +24.98% |
| Samsara BioCapital GP, LLC | 10 percent owner | 5074916 8.083% | $72.32M | 1 | 0 | <0.0001% |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 3218106 5.1256% | $45.86M | 1 | 0 | |
| RA CAPITAL MANAGEMENT, L.P. | director | 1867229 2.974% | $26.61M | 1 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$7,929,017 | 58 | 21.56% | $787.18M | |
$571,084,134 | 44 | 4.33% | $988.55M | |
$97,176 | 41 | 42.84% | $802.16M | |
$28,907,358 | 35 | 41.41% | $899.09M | |
$530,111,731 | 35 | 8.67% | $1.09B |
MLYS Institutional Investors: Active Positions
| Increased Positions | 62 | +68.13% | 4M | +9.36% |
| Decreased Positions | 31 | -34.07% | 2M | -4.58% |
| New Positions | 17 | New | 889,964 | New |
| Sold Out Positions | 15 | Sold Out | 1M | Sold Out |
| Total Postitions | 122 | +34.07% | 46M | +4.78% |
MLYS Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Catalys Pacific, Llc | $79,011.00 | 17.29% | 8.64M | 0 | 0% | 2024-12-31 |
| Samsara Biocapital, Llc | $46,385.00 | 10.15% | 5.07M | 0 | 0% | 2024-12-31 |
| Ra Capital Management, L.P. | $44,338.00 | 9.7% | 4.85M | 0 | 0% | 2024-12-31 |
| Tcg Crossover Management, Llc | $22,578.00 | 4.94% | 2.47M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $19,546.00 | 4.28% | 2.14M | -5,646 | -0.26% | 2024-12-31 |
| Sr One Capital Management, Lp | $18,434.00 | 4.03% | 2.02M | 0 | 0% | 2024-12-31 |
| Franklin Resources Inc | $15,955.00 | 3.49% | 1.75M | +84 | +<0.01% | 2024-12-31 |
| Orbimed Advisors Llc | $14,730.00 | 3.22% | 1.61M | -391,302 | -19.54% | 2024-12-31 |
| Vanguard Group Inc | $13,089.00 | 2.86% | 1.43M | +68,811 | +5.05% | 2024-12-31 |
| Laurion Capital Management Lp | $12,909.00 | 2.83% | 1.41M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.